We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

35 hedge funds and large institutions have $296M invested in X4 Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

133% more funds holding

Funds holding: 15 → 35 (+20)

84% more capital invested

Capital invested by funds: $161M → $296M (+$135M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.01% less ownership

Funds ownership: 0.42% → 0.42% (-0.01%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
35
Holders Change
+20
Holders Change %
+133.33%
% of All Funds
0.8%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
25
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.85M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2.64M
3
First Eagle Investment Management
First Eagle Investment Management
New York
+$2.01M
4
State Street
State Street
Massachusetts
+$911K
5
BCM
Bridgeway Capital Management
Texas
+$786K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$2.49M
2
DM
Deerfield Management
New York
-$1.68M
3
LCM
Landscape Capital Management
New Jersey
-$504K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$460K
5
Millennium Management
Millennium Management
New York
-$299K
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
26
STRS Ohio
Ohio
$29K +$20.4K +7 New
Barclays
27
Barclays
United Kingdom
$22K +$14.5K +5 New
CHP
28
Cable Hill Partners
Oregon
$22K +$17.5K +6 New
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$18.2K +$11.6K +4 New
Legal & General Group
30
Legal & General Group
United Kingdom
$18K +$11.6K +4 New
Manulife (Manufacturers Life Insurance)
31
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$16K +$11.6K +4 New
Citigroup
32
Citigroup
New York
$14K -$2.91K -1 -25%
AIP
33
Ameritas Investment Partners
Nebraska
$9K +$5.82K +2 New
Bank of America
34
Bank of America
North Carolina
$8K +$5.82K +2 New
KF
35
Krilogy Financial
Missouri
$5K +$2.91K +1 New
DM
36
Deerfield Management
New York
– -$1.68M -731 Closed
LCM
37
Landscape Capital Management
New Jersey
– -$504K -220 Closed
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
– -$460K -200 Closed
Millennium Management
39
Millennium Management
New York
– -$299K -130 Closed
LCM
40
Laurion Capital Management
New York
– -$191K -83 Closed
1
2

XFOR Hedge Fund Activity: Q1 2018 in Review

35 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2018, worth a combined $296M — up 84% from $161M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new XFOR positions and 5 closed out — a net gain of 20 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $2.85M. The largest seller was Sphera Funds Management, cutting an estimated $2.49M.

  • 35 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2018, up from 15 in Q4 2017.
  • Funds reported $296M of X4 Pharmaceuticals stock for Q1 2018, up 84% quarter-over-quarter.
  • 25 funds opened new X4 Pharmaceuticals positions in Q1 2018 and 5 closed out, a net change of +20 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2018 was BlackRock, an estimated $2.85M added.
  • The largest X4 Pharmaceuticals seller in Q1 2018 was Sphera Funds Management, an estimated $2.49M sold.

Based on aggregated 13F filings for Q1 2018.